• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用新型仪器内标加样法和析因设计建立 UPLC 同时测定几种 COVID-19 药物的方法。

Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design.

机构信息

Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.

Pharmaceutical Chemistry Department, Egyptian Drug Authority (EDA), Cairo, Egypt.

出版信息

Sci Rep. 2023 Apr 4;13(1):5466. doi: 10.1038/s41598-023-32405-x.

DOI:10.1038/s41598-023-32405-x
PMID:37016018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10071232/
Abstract

A green, rapid, and simple RP-UPLC method was developed and optimized by full factorial design for the simultaneous separation of oseltamivir phosphate, daclatasivir dihydrochloride, and remdesivir, with dexamethasone as a co-administered drug. The separation was established on a UPLC column BEH C 1.7 µm (2.1 × 100.0 mm) connected with a UPLC pre-column BEH 1.7 µm (2.1 × 5.0 mm) at 25 °C with an injection volume of 10 µL. The detector (PDA) was set at 239 nm. The mobile phase consisted of methanol and ammonium acetate (8.1818 mM) in a ratio of 75.7: 24.3 (v/v). The flow rate was set at 0.048 mL min. The overall separation time was 9.5 min. The retention times of oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir were 6.323 ± 0.145, 7.166 ± 0.036, 8.078 ± 0.124, and 8.572 ± 0.166 min (eight replicates), respectively. The proposed method demonstrated linearity in the ranges of 10.0-500.0 (ng mL) and 0.5-30.0 (µg mL) for oseltamivir phosphate, 50.0-5000.0 (ng mL) for dexamethasone, 25.0-1000.0 (ng mL) and 0.5-25.0 (µg mL) for daclatasvir dihydrochlorde, and 10.0-500.0 (ng mL) and 0.5-30.0 (µg mL) for remdesivir. The coefficients of determination (R) were greater than 0.9999, with percentage recoveries greater than 99.5% for each drug. The limits of quantitation were 6.4, 1.8, 7.8, and 1.6 ng mL, and the limits of detection were 1.9, 0.5, 2.0, and 0.5 ng mL for oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir, respectively. The proposed method was highly precise, as indicated by the low percentage of relative standard deviation values of less than 1.2% for each drug. The average content and uniformity of dosage units in the studied drugs' dosage forms were determined. The average contents of oseltamivir phosphate, dexamethasone, daclatasivir dihydrochloride, and remdesivir were nearly 93%, 102%, 99%, and 95%, respectively, while the uniformity of dosage unit values were nearly 92%, 102%, 101%, and 97%. Two novel methods were established in this work. The first method was used to assess the stability of standard solutions. This novel method was based on the slope of regression equations. The second was to evaluate the excipient's interference using an innovative instrumental standard addition method. The novel instrumental standard addition method was performed using the UPLC instrument program. It was more accurate, sensitive, time-saving, economical, and eco-friendly than the classic standard addition method. The results showed that the proposed method can estimate the tested drugs' concentrations without interference from their dosage form excipients. According to the Eco-score (more than 75), the Green Analytical Procedure Index (GAPI), and the AGREE criteria (total score of 0.77), the suggested method was considered eco-friendly.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19b/10073143/1562f7db071c/41598_2023_32405_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19b/10073143/2d17cc5d3654/41598_2023_32405_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19b/10073143/8038073a5552/41598_2023_32405_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19b/10073143/1562f7db071c/41598_2023_32405_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19b/10073143/2d17cc5d3654/41598_2023_32405_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19b/10073143/8038073a5552/41598_2023_32405_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d19b/10073143/1562f7db071c/41598_2023_32405_Fig3_HTML.jpg
摘要

建立并优化了一种采用全因子设计的绿色、快速、简单的 RP-UPLC 方法,用于同时分离奥司他韦磷酸盐、达拉他韦二盐酸盐和瑞德西韦,并用地塞米松作为共同给药药物。分离在 UPLC 柱 BEH C1.7µm(2.1×100.0mm)上进行,与 UPLC 预柱 BEH 1.7µm(2.1×5.0mm)相连,在 25°C 下以 10µL 的进样量进行注射。检测器(PDA)设置在 239nm。流动相由甲醇和乙酸铵(8.1818mM)以 75.7:24.3(v/v)的比例组成。流速设定为 0.048mL/min。总分离时间为 9.5min。奥司他韦磷酸盐、地塞米松、达拉他韦二盐酸盐和瑞德西韦的保留时间分别为 6.323±0.145、7.166±0.036、8.078±0.124 和 8.572±0.166min(8 次重复)。所提出的方法在奥司他韦磷酸盐 10.0-500.0(ng mL)和 0.5-30.0(µg mL)、地塞米松 50.0-5000.0(ng mL)、达拉他韦二盐酸盐 25.0-1000.0(ng mL)和 0.5-25.0(µg mL)以及瑞德西韦 10.0-500.0(ng mL)和 0.5-30.0(µg mL)的范围内表现出线性。测定的相关系数(R)均大于 0.9999,每种药物的回收率均大于 99.5%。奥司他韦磷酸盐、地塞米松、达拉他韦二盐酸盐和瑞德西韦的定量限分别为 6.4、1.8、7.8 和 1.6ng mL,检测限分别为 1.9、0.5、2.0 和 0.5ng mL。所提出的方法具有较高的精密度,每个药物的相对标准偏差(RSD)值均小于 1.2%。研究药物剂型的平均含量和均匀度。奥司他韦磷酸盐、地塞米松、达拉他韦二盐酸盐和瑞德西韦的平均含量分别接近 93%、102%、99%和 95%,而单位剂量值的均匀度分别接近 92%、102%、101%和 97%。本工作建立了两种新方法。第一种方法用于评估标准溶液的稳定性。这种新方法基于回归方程的斜率。第二种方法是使用创新的仪器标准加入法评估赋形剂的干扰。新的仪器标准加入法是在 UPLC 仪器程序中进行的。与经典标准加入法相比,该方法更准确、灵敏、省时、经济和环保。结果表明,该方法可以在不干扰药物制剂赋形剂的情况下估算被测药物的浓度。根据生态评分(大于 75)、绿色分析程序指数(GAPI)和 AGREE 标准(总分为 0.77),该方法被认为是环保的。

相似文献

1
Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design.利用新型仪器内标加样法和析因设计建立 UPLC 同时测定几种 COVID-19 药物的方法。
Sci Rep. 2023 Apr 4;13(1):5466. doi: 10.1038/s41598-023-32405-x.
2
UPLC-PDA factorial design assisted method for simultaneous determination of oseltamivir, dexamethasone, and remdesivir in human plasma.UPLC-PDA 析因设计辅助法同时测定人血浆中奥司他韦、地塞米松和瑞德西韦。
Sci Rep. 2024 Sep 18;14(1):21758. doi: 10.1038/s41598-024-71413-3.
3
A quality-by-design eco-friendly UV-HPLC method for the determination of four drugs used to treat symptoms of common cold and COVID-19.采用质量源于设计的环保型紫外-高效液相色谱法测定四种用于治疗普通感冒和 COVID-19 症状的药物。
Sci Rep. 2023 Jan 28;13(1):1616. doi: 10.1038/s41598-023-28737-3.
4
[Simultaneous determination of 29 pesticides residues in bayberry by pass-through solid-phase extraction and ultra-performance liquid chromatography-high resolution mass spectrometry].[采用在线固相萃取-超高效液相色谱-高分辨质谱联用法同时测定杨梅中29种农药残留]
Se Pu. 2021 Jun;39(6):614-623. doi: 10.3724/SP.J.1123.2020.11011.
5
Development and Validation of HPLC Fluorescence and UPLC/DAD Stability-Indicating Methods for Determination of Hepatitis C Antiviral Agent Daclatasvir.用于测定丙型肝炎抗病毒药物达卡他韦的高效液相色谱荧光法和超高效液相色谱/二极管阵列检测稳定性指示方法的开发与验证
J AOAC Int. 2019 Jul 1;102(4):1125-1131. doi: 10.5740/jaoacint.18-0344. Epub 2019 Apr 2.
6
Stability-Indicating New RP-UPLC Method for Simultaneous Determination of a Quaternary Mixture of Paracetamol, Pseudoephedrine, Chlorpheniramine, and Sodium Benzoate in (Cold-Flu) Syrup Dosage Form.用于同时测定(感冒-流感)糖浆剂型中对乙酰氨基酚、伪麻黄碱、氯苯那敏和苯甲酸钠四元混合物的稳定性指示新型反相超高效液相色谱法
J AOAC Int. 2022 Apr 27;105(3):703-716. doi: 10.1093/jaoacint/qsac002.
7
[Simultaneous determination of ibuprofen and arginine in ibuprofen injection using ultra performance liquid chromatography].[采用超高效液相色谱法同时测定布洛芬注射液中布洛芬和精氨酸的含量]
Se Pu. 2011 Oct;29(10):1005-9.
8
Green analytical quality by design RP-HPLC technique with fluorimetric detection for simultaneous assay of cinnarizine and dompridone.采用荧光检测的绿色分析质量源于设计的反相高效液相色谱法同时测定桂利嗪和多潘立酮
R Soc Open Sci. 2024 Jul 17;11(7):240829. doi: 10.1098/rsos.240829. eCollection 2024 Jul.
9
[Simultaneous determination of 11 prohibited and restricted veterinary drugs and their metabolites in animal-derived foods by ultra performance liquid chromatography-tandem mass spectrometry coupled with solid phase extraction].超高效液相色谱-串联质谱联用固相萃取法同时测定动物源性食品中11种禁用和限用兽药及其代谢物
Se Pu. 2021 Apr 8;39(4):406-414. doi: 10.3724/SP.J.1123.2020.05012.
10
Analytical quality-by-design approach for development and validation of HPLC method for the simultaneous estimation of omarigliptin, metformin, and ezetimibe: application to human plasma and dosage forms.采用分析质量源于设计的方法开发和验证同时测定奥格列汀、二甲双胍和依折麦布的高效液相色谱法:应用于人体血浆和剂型
BMC Chem. 2023 May 5;17(1):45. doi: 10.1186/s13065-023-00955-w.

引用本文的文献

1
UPLC-PDA factorial design assisted method for simultaneous determination of oseltamivir, dexamethasone, and remdesivir in human plasma.UPLC-PDA 析因设计辅助法同时测定人血浆中奥司他韦、地塞米松和瑞德西韦。
Sci Rep. 2024 Sep 18;14(1):21758. doi: 10.1038/s41598-024-71413-3.
2
Interaction mechanism of oseltamivir phosphate with bovine serum albumin: multispectroscopic and molecular docking study.磷酸奥司他韦与牛血清白蛋白的相互作用机制:多光谱和分子对接研究
BMC Chem. 2024 Jul 5;18(1):126. doi: 10.1186/s13065-024-01232-0.

本文引用的文献

1
Rapid and ecofriendly UPLC quantification of Remdesivir, Favipiravir and Dexamethasone for accurate therapeutic drug monitoring in Covid-19 Patient's plasma.快速且环保的超高效液相色谱法对瑞德西韦、法匹拉韦和地塞米松进行定量分析,用于准确监测新冠肺炎患者血浆中的治疗药物。
Microchem J. 2022 Aug;179:107580. doi: 10.1016/j.microc.2022.107580. Epub 2022 May 13.
2
Structural characterization of methyl-β-cyclodextrins by high-performance liquid chromatography and nuclear magnetic resonance spectroscopy and effect of their isomeric composition on the capillary electrophoresis enantioseparation of daclatasvir.采用高效液相色谱和核磁共振波谱对甲基-β-环糊精进行结构表征,并研究其同分异构组成对达芦那韦毛细管电泳手性分离的影响。
J Chromatogr A. 2022 Jan 4;1661:462675. doi: 10.1016/j.chroma.2021.462675. Epub 2021 Nov 9.
3
Accelerated stability study of the ester prodrug remdesivir: Recently FDA-approved Covid-19 antiviral using reversed-phase-HPLC with fluorimetric and diode array detection.酯前药瑞德西韦的稳定性加速研究:最近 FDA 批准的用于治疗 COVID-19 的抗病毒药物,采用反相高效液相色谱法,荧光和二极管阵列检测。
Biomed Chromatogr. 2021 Dec;35(12):e5212. doi: 10.1002/bmc.5212. Epub 2021 Aug 9.
4
Green and sensitive spectrofluorimetric determination of Remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma.绿色敏感的荧光光度法测定瑞德西韦,一种获得 FDA 批准的 SARS-CoV-2 候选抗病毒药物;在药物制剂和加标人血浆中的应用。
Anal Methods. 2021 Jun 21;13(23):2596-2602. doi: 10.1039/d1ay00469g. Epub 2021 May 21.
5
A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019.索磷布韦和达卡他韦治疗2019冠状病毒病的综述
New Microbes New Infect. 2021 Jul;42:100895. doi: 10.1016/j.nmni.2021.100895. Epub 2021 May 7.
6
Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma.开发并验证了一种简单、选择性强、灵敏度高的液相色谱-串联质谱法,用于人血浆中瑞德西韦的定量分析。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 May 1;1171:122641. doi: 10.1016/j.jchromb.2021.122641. Epub 2021 Mar 10.
7
Rapid and simultaneous determination of dexamethasone and dexamethasone sodium phosphate using HPLC-UV: Application in microneedle-assisted skin permeation and deposition studies.高效液相色谱-紫外法快速同时测定地塞米松及其磷酸钠盐:在微针辅助经皮渗透和沉积研究中的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Apr 30;1170:122609. doi: 10.1016/j.jchromb.2021.122609. Epub 2021 Mar 1.
8
Chinese guidelines related to novel coronavirus pneumonia.新型冠状病毒肺炎相关中国指南。
J Mark Access Health Policy. 2020 Oct 8;8(1):1818446. doi: 10.1080/20016689.2020.1818446.
9
Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study.奥司他韦是否适合对抗 COVID-19:计算机评估、体外和回顾性研究。
Bioorg Chem. 2020 Nov;104:104257. doi: 10.1016/j.bioorg.2020.104257. Epub 2020 Sep 2.
10
AGREE-Analytical GREEnness Metric Approach and Software.AGREE-分析 GREEnness 度量方法和软件。
Anal Chem. 2020 Jul 21;92(14):10076-10082. doi: 10.1021/acs.analchem.0c01887. Epub 2020 Jun 30.